Mod­er­na cuts four pro­grams in vac­cines, sol­id tu­mors and heart fail­ure as it in­creas­es, pri­or­i­tizes pipeline

Mod­er­na is beef­ing up its pipeline over the next five years with a plan launch up to 15 new prod­ucts and ad­vance up to 50 mR­NA med­i­cines in­to clin­i­cal tri­als — but not all pro­grams made the cut as the com­pa­ny pri­or­i­tizes.

Four pro­grams were scrapped, ac­cord­ing to Mod­er­na’s R&D day pre­sen­ta­tion for in­vestors. The list in­cludes a first-gen­er­a­tion Covid and flu com­bo vac­cine and an­oth­er vac­cine for pe­di­atric hu­man metap­neu­movirus (hM­PV) and parain­fluen­za type 3. Round­ing out the list is an mR­NA prospect for sol­id tu­mors that en­cod­ed for the cy­tokine IL-12, and an­oth­er can­di­date that en­cod­ed for vas­cu­lar en­dothe­lial growth fac­tor A (VEGF-A) in pa­tients un­der­go­ing coro­nary artery by­pass graft­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER